California - based Ambys Medicines has launched with $ 140 m in funding to develop treatments for serious liver diseases . The company raised $ 60 m in a series A funding round led by Third Rock Ventures and Japan ’s Mitsubishi , while another $ 60 m was secured through a further funding agreement with Takeda . Ambys will focus on the development of therapeutic modalities such as cell therapy , hepatocyte transplantation and gene therapy for the treatment of patients with chronic liver diseases .
California-based Ambys Medicines has launched with $140m in funding to develop treatments for serious liver diseases. The company raised $60m in a series A funding round led by Third Rock Ventures and Japan’s Takeda, while another $80m was secured through a further partnership agreement with Takeda. Ambys will focus on the development of therapeutic modalities such as cell therapy, hepatocyte transplantation and gene therapy for the treatment of patients with chronic liver diseases.